Tianda Pharmaceuticals Plans to Launch 100 TDMalls and Explores New Markets (Ming Pao)

03.08.2020

Mr. Fang Wenquan, Chairman of Tianda Pharmaceuticals Ltd. (0455.HK), said that the Group would invest about RMB200 million in the Guangdong, Hong Kong and Macao Greater Bay Area in the next three years in the expansion of its Chinese medicine clinic chain - TDMall, while exploring development opportunities in the innovative medicine market.

“Some anti-viral drugs such as Ribavirin were sold out during the epidemic outbreak”, Fang said. At the same time, his team had worked with mainland’s Traditional Chinese medicine experts to develop an “Anti-Epidemic Formula 1”, which is said to be able to prevent a coronavirus. The product has been approved for entry into the Australian Register of Therapeutic Goods as a listed medicine and is expected to be available in the country in August.

The Company’s modern style Chinese medicine clinic chain segment, TDMall, is expected to break even in the second half of the year. Ms. Yeung Ming Ha, Chief Executive Officer of TDMall (Group) Ltd. said, ”We currently have a team of more than 100 people, covering ten specialties in Chinese medicine, including Chinese medicine gynecology, pediatrics, geriatrics, orthopedics and pain, cosmetology, etc. Zhuhai TDMall has also launched a Womb Caring Centre and a Health Management Center specializing in urban diseases and pain management, and while focusing on improving the assessment, training and inheritance of the practitioners”. In the midst of the epidemic, the Group has created “Cloud TDMall” for remote consultation. In addition, the Company’s Zhuhai Jinwan pharmaceutical manufacturing and R&D base is expected to be completed by the end of this year. Mr. Fang said “together with the existing pharmaceutical plants, we will establish a foundation to develop innovative drugs on our own or through collaborations, and also intend to enter into the medical technology business.”

Source: Mingpao

This is an English translation of the original Chinese text. If there is any inconsistency or ambiguity between the English version and the Chinese version, the Chinese version shall prevail.